Table 1. Baseline patient and disease characteristics, and prior procedures (N=606).
| Parameter | Data |
|---|---|
| Gender, N (%) | |
| Female | 233 (38.4) |
| Male | 373 (61.6) |
| Age, mean ± SD (range) (years) | 61.5±12.7 (20.8-91.9) |
| Race, N (%)xiv | |
| White or Caucasian | 398 (77.7) |
| Black or African American | 67 (13.1) |
| Hispanic or Latino | 17 (3.3) |
| Asian | 12 (2.3) |
| Other | 18 (3.5) |
| ECOG performance status, N (%)xvi | |
| 0 | 168 (65.4) |
| 1 | 72 (28.0) |
| 2 | 14 (5.4) |
| 3 | 3 (1.2) |
| Site of primary, N (%)i | |
| Colon | 443 (73.3) |
| Rectum | 133 (22.0) |
| Colorectal | 28 (4.6) |
| Primary tumor in situ, N (%)iii | 78 (13.0) |
| Metastases (%)xi* | |
| Synchronous | 396 (69.6) |
| Extrahepatic metastases, N (%) | |
| Yes | 213 (35.1) |
| No | 393 (64.9) |
| Lung | 148 (24.4) |
| Lymph node | 67 (11.1) |
| Peritoneum | 17 (2.8) |
| Bone | 30 (5.0) |
| Other | 38 (6.3) |
| Carcinoembryonic antigen, median (IQR) (µg/L)xv | 62.2 (283.4) |
| Ascites, N (%)vii | |
| Yes | 28 (4.7) |
| Prior liver-directed procedures, N (%) | |
| Any | 183 (30.2) |
| Surgery and/or ablation | 168 (27.7) |
| Vascular therapy (HAI, TACE, TAE) | 37 (6.1) |
| Upper abdominal radiation | 7 (1.2) |
| Stereotactic external beam radiotherapy | 4 (0.7) |
| Prior lines of systemic chemotherapy for mCRC, N (%) | |
| None (90Y-RE at 1st-line) | 35 (6.0) |
| 1 line (90Y-RE at 2nd-line) | 206 (35.3) |
| 2 lines (90Y-RE at 3rd-line) | 184 (31.6) |
| ≥3 lines (90Y-RE at ≥4th-line) | 158 (27.1) |
| Unknown | 23 (3.8) |
| Time from mCRC diagnosis to RE, median (range) (months)x | 16.3 (0.4-96.3) |
| Albumin, median (IQR) (g/dL)viii | 3.7 (0.8) |
| Total bilirubin, median (IQR) (mg/dL)vi | 0.6 (0.5) |
| Alkaline phosphatase, median (IQR) (U/L)vii | 146.0 (143.0) |
| Alanine transaminase, median (IQR) (U/L)x | 30.0 (24.0) |
| Aspartate aminotransferase, median (IQR) (U/L)ix | 35.0 (29.0) |
| Creatinine, median (IQR) (mg/dL)iv | 0.9 (0.3) |
| Hemoglobin, median (IQR) (g/dL)v | 12.4 (2.6) |
| Platelets, median (IQR) (×109/L)iv | 213.0 (121.0) |
| Neutrophils, median (IQR) (×109/L)xviii | 4.1 (2.1) |
| Lymphocytes, median (IQR) (×109/L)xvii | 1.2 (0.7) |
| Tumor-to-target liver involvement at first 90Y-RE, median (range) (%)xiii | 15% (0.1-100) |
| Tumor-to-target liver at first 90Y-RE, N (%)xiii | |
| <25% | 388 (69.5) |
| 25-50% | 148 (26.5) |
| >50% | 22 (3.9) |
| Overall tumor-to-target liver involvement, median (range) (%)xii | 15% (0.1-100) |
| Treated target, N (%)i | |
| Whole-liver, single-session ± retreatment | 179 (29.5) |
| Whole-liver, sequential | 218 (36.0) |
| Right lobe ± segmental | 168 (27.7) |
| Left lobe ± segmental | 33 (5.4) |
| Segmental | 5 (0.8) |
| Activity administered, median (range) (GBq)ii | |
| First treatment | 1.17 (0.11-2.29) |
| All treatments | 1.46 (0.11-5.51) |
Missing patient baseline data on: i, 2 patients; ii, 4 patients; iii, 6 patients; iv, 11 patients; v, 12 patients; vi, 13 patients; vii, 15 patients; viii, 16 patients; ix, 22 patients; x, 29 patients; xi, 37 patients; xii, 47 patients; xiii, 48 patients; xiv, 94 patients; xv, 176 patients; xvi, 349 patients; xvii, 458 patients; xviii, 479 patients; *, synchronous defined as the identification of metastases within 4 months (120 days) of the primary. HAI, hepatic arterial infusion chemotherapy; TACE, transarterial chemoembolization; TAE, transarterial embolization; IQR, interquartile range.